Dermata clears Australian patent hurdle for topical dermal fillers If issued, it would be Dermata's first patent on using Bioneedle with dermal fillers. The Australian filing auto-issues in three months absent opposition.

#DRMA #DRMAW Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

www.stocktitan.net/news/DRMA/dermata-receiv...

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 - Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome -- Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle of 2026 -- Raised

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

www.stocktitan.net/news/DRMA/dermata-therap...

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office Dermata (NASDAQ:DRMA) announced the Australian Patent Office granted Australian Patent No. 2019419387 for its Spongilla technology combination as a method to treat acne on January 20, 2026. This follows an already-issued U.S. patent covering the same technology. Dermata plans to launch a once-weekly, over-the-counter acne treatment system incorporating Spongilla in mid-2026 in the U.S. The company said the granted patent strengthens its global intellectual property estate, with additional patent filings pending in other jurisdictions and Australia cited as a key future market.

#DRMA #DRMAW Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

www.stocktitan.net/news/DRMA/dermata-receiv...

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules $4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrantsSAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader

#DRMA #DRMAW Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/DRMA/dermata-therap...

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Dermata Therapeutics (Nasdaq: DRMA) announced a strategic pivot to develop and commercialize over-the-counter dermatology products and reported Q3 2025 results. The company plans to launch a once-weekly acne kit using its Spongilla technology in mid-2026 and is developing branding, packaging, and manufacturing for direct-to-consumer and professional sales.Recent clinical progress includes positive topline Phase 3 STAR-1 results that met all three primary endpoints and showed separation from placebo by week 4. As of September 30, 2025, Dermata had $4.7 million in cash and expects funding into Q2 2026.

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

Once-Weekly Acne Treatment Breakthrough: Dermata's Novel Technology Gets Australian Patent Green Light Dermata's Spongilla technology for once-weekly OTC acne treatment receives Australian patent acceptance. Set to launch mid-2026, targeting 3.3M Australian acne patients.

#DRMA #DRMAW Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

www.stocktitan.net/news/DRMA/dermata-announ...

Once-Weekly Acne Treatment Breakthrough: Dermata's XYNGARI Phase 3 Results Coming to Major European Congress Dermata Therapeutics to present Phase 3 STAR-1 trial results for XYNGARI (DMT310), a novel once-weekly topical treatment for moderate-to-severe acne, at EADV Congress 2025 in Paris.

#DRMA #DRMAW Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

www.stocktitan.net/news/DRMA/dermata-therap...

50 Million Patient Market: Dermata's Strategic Shift to OTC Could Revolutionize Acne Treatment Access Biotech firm Dermata transitions from prescription drugs to OTC skincare, leveraging Spongilla technology for new acne treatment launching mid-2026. Strategic pivot aims to reach broader consumer base.

#DRMA #DRMAW Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

www.stocktitan.net/news/DRMA/dermata-therap...

New Acne Treatment XYNGARI Shows Success in Just 4 Weeks - Phase 3 Trial Results Revealed Dermata's XYNGARI achieves statistically significant results for moderate-to-severe acne in Phase 3 trial, with efficacy shown at 4 weeks. Funding secured through Q2 2026. Learn more.

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

Breakthrough: First-Ever Topical Botulinum Toxin for Hyperhidrosis Receives Australian Patent Dermata secures Australian patent for innovative DMT410 topical botulinum toxin delivery system. Partners with Revance for clinical trials. Learn about this breakthrough.

#DRMA #DRMAW Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

www.stocktitan.net/news/DRMA/dermata-receiv...

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Dermata Therapeutics (NASDAQ: DRMA) reported significant progress in Q1 2025, highlighted by positive topline results from its XYNGARI™ Phase 3 STAR-1 clinical trial for moderate-to-severe acne treatment. The trial achieved all three co-primary endpoints with statistical significance versus placebo, showing efficacy after just 4 weeks. The company also entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 with DAXXIFY® for axillary hyperhidrosis treatment.Financially, Dermata raised $8.8 million in gross proceeds during Q1 2025, ending the quarter with $9.7 million in cash. R&D expenses decreased to $1.3 million from $1.6 million year-over-year, while G&A expenses reduced to $1.1 million from $1.6 million. The company expects current cash resources to fund operations into Q1 2026.The company plans to initiate its second Phase 3 STAR-2 trial by end of 2025 and is in partnership discussions for XYNGARI™.

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks Dermata Therapeutics (NASDAQ:DRMA) has announced additional positive results from its Phase 3 STAR-1 trial for XYNGARI™, a potential first-ever once-weekly topical treatment for moderate-to-severe acne. The trial demonstrated statistically significant efficacy after just four treatments at week 4.Key results at week 4 showed:11.9% of XYNGARI™ patients achieved IGA treatment success vs 6.2% for placebo (pMean inflammatory lesion count reduction of -11.4 for XYNGARI™ vs -8.6 for placebo (pMean non-inflammatory lesion count reduction of -12.4 for XYNGARI™ vs -8.8 for placebo (pThe STAR-1 study enrolled 520 patients aged 9+ years across the US and Latin America in a 2:1 randomized, double-blind, placebo-controlled trial. This is the first of two pivotal Phase 3 studies, with successful results potentially supporting a future FDA new drug application.

#DRMA #DRMAW Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

www.stocktitan.net/news/DRMA/dermata-s-xyng...

Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement Biotech firm secures immediate $6.2M through warrant restructuring, strengthening cash position for clinical trials and R&D pipeline. Full investment implications inside.

#DRMA #DRMAW Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/DRMA/dermata-therap...

First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial Novel once-weekly XYNGARI shows significant efficacy in 520-patient Phase 3 trial for moderate-severe acne. Strong safety profile positions treatment for FDA submission.

#DRMA #DRMAW BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

www.stocktitan.net/news/DRMA/breaking-derma...

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results Dermata Therapeutics (NASDAQ:DRMA) provided its year-end 2024 financial results and corporate updates. The company expects to announce topline results from its XYNGARI™ Phase 3 STAR-1 clinical trial for moderate-to-severe acne by end of March 2025.Key financial highlights include:Cash position of $3.2M as of December 31, 2024R&D expenses increased to $8.2M in 2024 from $4.1M in 2023G&A expenses rose to $4.3M from $4.0M year-over-yearRaised $7.8M in gross proceeds during 2024Notable developments include a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 for axillary hyperhidrosis treatment, and a $2.55M private placement in January 2025. The company expects current cash resources to fund operations into Q3 2025.

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

Can Dermata's Once-Weekly Acne Treatment Disrupt a 30M-Patient Market? Final patient completes STAR-1 trial for novel once-weekly acne therapy targeting 30M+ patients annually. Topline results expected by March 2025.

#DRMA #DRMAW Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

www.stocktitan.net/news/DRMA/dermata-announ...

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis Dermata Therapeutics (NASDAQ: DRMA) announced the Australian Patent Office has accepted its patent application for the DMT410 program for treating hyperhidrosis. This would be Dermata's second patent for DMT410, which uses Spongilla technology to topically deliver botulinum toxin for excessive sweating treatment.The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for axillary hyperhidrosis. The upcoming Phase 2a study will explore DMT410's combination of a single XYNGARI™ application followed by a topical application of DAXXIFY®.Gerry Proehl, Dermata's Chairman, President, and CEO, stated the acceptance further validates DMT410's innovative approach. Beyond hyperhidrosis, the company believes DMT410 holds promise for treating various skin conditions, including acne, rosacea, melasma, acne scars, and other aesthetic concerns.The patent, entitled "Compositions for the treatment of skin conditions," will be automatically issued three months after acceptance unless opposed by a third party. Dermata also has an issued patent in Japan covering their DMT410 program for hyperhidrosis treatment.

#DRMA #DRMAW Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

www.stocktitan.net/news/DRMA/dermata-receiv...

Dermata Therapeutics Secures $2.55M Private Placement with Strong Insider Participation Dermata raises $2.55M through share & warrant offering at $1.27/share, backed by CEO & board member investments. Funding targets research, clinical trials & working capital.

#DRMA #DRMAW Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/DRMA/dermata-therap...

Dermata and Revance Partner on First Needle-Free Botulinum Treatment for Excessive Sweating Phase 2a trial combines Xyngari's innovative delivery system with Daxxify for treating hyperhidrosis, potentially revolutionizing treatment without needles. 48 patients to be evaluated.

#DRMA #DRMAW Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

www.stocktitan.net/news/DRMA/dermata-and-re...

Dermata Completes Phase 3 Trial Enrollment for Novel Weekly Acne Treatment | DRMA Stock News Dermata Therapeutics reaches milestone with 520 patients enrolled in pivotal Phase 3 STAR-1 trial for DMT310, a potential first-in-class weekly acne treatment. Results due March 2025.

#DRMA #DRMAW Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

#clinicaltrial #StockMarket #news

www.stocktitan.net/news/DRMA/dermata-comple...

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...